BOC Sciences provides integrated hit-to-lead drug discovery services that convert validated screening hits into high-quality lead series. Backed by medicinal chemistry, structural biology, computational design, custom synthesis, and early ADME profiling, we help research teams move from initial biological activity toward leads with improved potency, selectivity, and developability. Each project is managed under clear quality assurance and quality control practices so that chemistry, biology, and analytical data stay aligned throughout the program.
Hit-to-lead (H2L) is the discovery stage in which confirmed active compounds are converted into credible lead series. The work begins by removing assay artifacts and comparing chemical scaffolds, then uses structure-activity relationship (SAR) studies to improve potency, selectivity, physicochemical behavior, and early ADMET properties. The objective is not simply to find the most active molecule, but to identify a tractable series with reproducible biology, practical synthesis, a clear optimization path, and enough supporting data to enter lead optimization.
We begin by confirming that hits are reproducible and worth pursuing, using orthogonal assays to rule out false positives and technical artifacts before committing synthetic effort.
We group confirmed hits by chemical scaffold and identify privileged cores that can serve as efficient starting points for SAR exploration.
Our medicinal chemists improve early hits through focused SAR studies, iteratively modifying substituents to strengthen target engagement and drug-like behavior.
We support lead declaration by consolidating chemical, biological, and property data into a clear decision package for the client.
BOC Sciences helps research teams move from confirmed hits and scaffold selection to SAR-driven design, custom synthesis, iterative testing, and an application-ready lead series.
BOC Sciences provides customized hit-to-lead support across hit validation, scaffold analysis, SAR-driven synthesis, compound characterization, and early property screening. Key program categories include:
| Program Stage | Service Scope & Key Outputs |
| Hit Confirmation | Orthogonal re-testing, dose-response confirmation, counter-screening, and artifact exclusion to validate screening hits and remove false positives. |
| Scaffold Selection | Clustering of confirmed hits, identification of privileged scaffolds, and selection of representative series for early SAR studies. |
| Analog Synthesis | Parallel and focused synthesis of analogues, intermediates, and building blocks to explore substituent space and establish structure-activity relationships. |
| SAR & Potency Optimization | Iterative modification to improve target potency, selectivity against off-targets, and drug-like physicochemical properties across the series. |
| Early Property Screening | Solubility, permeability, metabolic stability, CYP inhibition, and lipophilicity profiling to flag developability risks early in the program. |
| Lead Declaration Support | Consolidation of chemistry, biology, and property data into a structured package that supports lead-series selection and handover to lead optimization. |
| In Vitro and In Vivo Profiling | Cell-based efficacy, target engagement, pharmacokinetic, and pharmacodynamic evaluation to strengthen the biological rationale for a selected lead. |
Share your hit structures, confirmed activity data, target biology, desired potency and selectivity goals, and property concerns. Our specialists will design a project-specific plan covering hit confirmation, scaffold selection, structure-activity relationship analysis, analog synthesis, early profiling, and lead declaration.
BOC Sciences reviews target biology, assay quality, compound structures, existing activity data, property results, and project constraints. The team then defines confirmation experiments, series-selection criteria, a target compound profile, and decision gates for the first optimization cycle.
Chemists design focused analog sets around explicit SAR or structure-based hypotheses, select practical synthetic routes, and prepare compounds through parallel or conventional synthesis. Purified products are structurally confirmed and registered with clear batch and analytical records before testing.
Each compound set moves through the agreed potency, selectivity, cell-response, physicochemical, and ADMET cascade. Integrated data analysis reveals productive substitutions and emerging liabilities, allowing the next design cycle to focus on the changes most likely to improve the full profile.
Compounds are compared with the target profile and project decision criteria. Clients receive selected lead and backup structures, synthesis and analytical records, assay and property data, SAR conclusions, remaining risk areas, and recommended next experiments in an organized project package.
Screening hits often show only micromolar potency or act on multiple related proteins, making them difficult to advance. BOC Sciences addresses this by combining SAR-guided synthesis with computational ranking and structural insight to strengthen target engagement and narrow the selectivity window. We use iterative design-make-test cycles so that each analogue set improves both potency and selectivity against closely related off-targets.
Some chemical series reach an activity plateau where simple substitutions no longer improve potency, or where SAR is flat and hard to interpret. BOC Sciences breaks through these limits by exploring alternative substitution vectors, scaffold hopping, and new linker and ring systems guided by co-crystal or docking data. We use orthogonal analytical confirmation to ensure observed changes reflect genuine biology rather than assay or solubility artifacts.
Potent compounds can fail early because of poor aqueous solubility, rapid metabolic clearance, or low permeability. BOC Sciences integrates ADMET screening into the hit-to-lead workflow so these liabilities are detected early rather than after significant synthesis investment. We apply property-informed design to improve solubility, metabolic stability, and permeability while preserving target potency and selectivity.
When chemistry and biology operate in separate silos, slow data turnaround and inconsistent assay data slow down the whole program. BOC Sciences provides an integrated workflow in which synthesis, purification, testing, and data interpretation are coordinated within a single team. This reduces the time between design and learning and ensures decisions are based on complete, aligned data packages.
Discuss your hit-to-lead challenges with BOC Sciences experts. Share your hit structures, assay data, potency, selectivity, or developability issues, and our team will help identify a practical path forward.
BOC Sciences combines medicinal chemistry, custom synthesis, structural biology, computational design, and early property screening in a single workflow. This integration helps clients avoid fragmented project execution and supports faster, better-informed decisions when chemistry, biology, and developability must be considered together.
We run efficient design-make-test-analyze (DMTA) cycles that turn biological and property data into the next round of design. This data-driven approach reduces wasted synthesis and helps clients reach meaningful SAR conclusions with fewer compounds and less time.
Whether a client needs support on a single hit series, a focused SAR package, or a full hit-to-lead program, BOC Sciences adapts the scope and depth to the program. We provide lead optimization and lead discovery support as natural extensions of the same workflow.
Reliable analogue data depends on clean compounds and correct structures. Our analytical platform supports HPLC, LC-MS, NMR, chiral analysis, and purity confirmation so that biological results can be attributed to the intended structure with confidence.
Client Needs: In this illustrative program, a discovery team had a heteroaryl kinase inhibitor series with reproducible low-micromolar biochemical activity but weak cellular response. The team needed to improve potency while retaining selectivity against closely related kinases.
Challenges: The original analogs varied mainly at one solvent-exposed position, and several more lipophilic compounds appeared potent only near their solubility limit. A credible binding pose and broader SAR map were required.
Solution: We confirmed activity with fresh material, modeled the ATP-site binding pose, and designed 24 analogs across hinge-binding, back-pocket, and solvent-exposed vectors. Two parallel synthesis rounds used Suzuki coupling and amide diversification, followed by preparative HPLC. LC-MS, NMR, enzyme assays, kinase counterscreens, solubility testing, and a cellular pathway assay guided each design decision.
Outcome: The example workflow identified a differentiated subseries with improved biochemical and cellular activity, cleaner family selectivity, and a better basis for continued property optimization.
Client Needs: An illustrative metabolic-enzyme program began with an active bicyclic scaffold that also inhibited two homologous enzymes. The desired lead needed to preserve pathway activity while widening biochemical selectivity.
Challenges: Potency and off-target activity moved together across the first analog set. Limited structural data made it difficult to determine whether the same interactions controlled both target and homolog binding.
Solution: We clustered prior data, built comparative binding models, and selected three substituent vectors predicted to contact nonconserved residues. Eighteen analogs were prepared by modular heterocycle synthesis and purified by flash chromatography or preparative HPLC. Target and homolog enzyme assays, thermal-shift measurements, LC-MS, NMR, permeability, and microsomal stability data were integrated through matched-pair analysis.
Outcome: The illustrative study separated the target-potency and homolog-selectivity trends, nominated a primary series, and defined two structural features for the next optimization cycle.
Client Needs: In this illustrative CNS project, a basic amine-containing lead showed strong cellular activity but low metabolic stability and inconsistent brain-exposure potential. The team wanted to preserve target engagement while improving the overall property profile.
Challenges: Reducing lipophilicity improved solubility but weakened permeability, while blocking one oxidative soft spot shifted metabolism to another ring position. The optimization required coordinated activity, metabolism, and transport data.
Solution: We mapped metabolic soft spots by LC-MS/MS, modeled pKa and CNS multiparameter scores, and designed 20 analogs using ring fluorination, heteroaryl replacement, and amine-basicity modulation. Parallel synthesis, chiral separation, NMR, biochemical and cellular assays, kinetic solubility, microsomal stability, plasma protein binding, and bidirectional permeability testing supported two iterative selection rounds.
Outcome: The example campaign produced a balanced backup series with improved metabolic stability and permeability while maintaining useful cellular target engagement for further study.
A hit is a compound that shows reproducible activity in an initial screening or confirmation assay, but it may still have weak potency, poor selectivity, assay interference, or unsuitable physicochemical properties. A lead is a more thoroughly characterized compound or series with convincing target-related activity, an interpretable structure-activity relationship, practical synthetic access, and a more balanced profile of potency, selectivity, solubility, permeability, and metabolic stability. Hit-to-lead work bridges this gap by validating activity and improving the chemical series through iterative design, synthesis, testing, and analysis.
The hit-to-lead process usually begins with confirmation of screening activity using concentration-response and orthogonal assays. Confirmed hits are then clustered by scaffold, reviewed for chemical tractability, and compared using potency, selectivity, ligand efficiency, and early property data. Medicinal chemists design and synthesize focused analogs to establish SAR, while biological and ADMET testing reveals productive modifications and emerging liabilities. Repeated design-make-test-analyze cycles refine the series until one or more compounds meet project-specific criteria for lead selection and continued optimization with greater scientific confidence.
A promising lead compound combines reproducible target activity with selectivity, useful cellular response, practical synthetic accessibility, and an understandable SAR. It should also display a balanced physicochemical and early ADMET profile rather than relying on potency alone. Relevant considerations may include solubility, permeability, metabolic stability, protein binding, lipophilicity, chemical stability, and the absence of obvious assay-interference or off-target liabilities. The exact acceptance criteria depend on the target, intended biological context, route of exposure, and project strategy, so leads are selected through multiparameter comparison rather than one universal cutoff.
Useful starting information includes the target and proposed mechanism, assay protocols, primary and confirmation data, hit structures, compound identifiers, available quantities, analytical records, and any known solubility or stability concerns. Clients should also describe desired potency, selectivity, cellular activity, and property goals, together with relevant counterscreens and previous optimization attempts. BOC Sciences uses these materials to assess data confidence, identify missing decision-critical experiments, define series-selection criteria, and propose an appropriate chemistry, biology, computational, structural, and ADMET workflow for the hit-to-lead project.
Yes. BOC Sciences can support a complete hit-to-lead program or selected activities that fill specific capability gaps. A project may focus on hit confirmation, scaffold clustering, computational modeling, focused analog design, custom synthesis, biological assays, SAR interpretation, physicochemical testing, ADMET profiling, or lead-series comparison. The scope can be organized around one chemical series or several competing scaffolds. Existing client data and internal capabilities are incorporated into the plan so that outsourced work answers defined project questions and integrates clearly with ongoing medicinal chemistry and discovery biology efforts.
BOC Sciences applied a thorough orthogonal confirmation workflow to our screening hits, helping us remove false positives and focus our synthesis budget on the most reproducible chemotypes. The structured prioritization was very useful for our team.
— Dr. Grayson, Senior Scientist, Oncology Discovery
The parallel synthesis and fast data turnaround allowed us to move through several design cycles quickly. BOC Sciences kept chemistry, testing, and interpretation closely coordinated, which made the whole hit-to-lead phase far more efficient.
— Townsend, Project Manager, Medicinal Chemistry
We appreciated the early ADME and solubility profiling that was built into the program. It helped us identify developability issues before we committed too much chemistry, and the property data guided the redesign in a clear direction.
— Dr. Neville, Lead DMPK Scientist
The final handover package was clear and well organized, with SAR summaries, selectivity data, and property profiles all aligned. BOC Sciences provided actionable recommendations that made the decision to advance a lead series straightforward for our group.
— Fletcher, Research Director, Drug Discovery
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
